New tendencies in the treatment of diabetic and cardiovascular diseases: a view of cardiologists


Cite item

Full Text

Abstract

The presented review discusses the modern tactics of treating patients with sugar type 2 diabetes The results of a large international placebo-controlled randomized clinical study EMPA-REG OUTCOME using empagliflozin selective inhibitor of sodium-dependent glucose transporter type 2. This drug was the first hypoglycemic drug that proved not only on the safety of cardiovascular effects, but also on the significant positive cardioprotective effect in patients with type 2 diabetes. Presented by indications for its purpose in clinical practice

About the authors

I. Z Bondarenko

National Medical Research Center of Endocrinology

Email: iz_bondarenko@mail.ru
д-р мед. наук, гл. науч. сотр. отд. кардиологии, эндоваскулярной и сосудистой хирургии 117036, Russian Federation, Moscow, ul. Dmitriia Ul'ianova, d. 11, k. 2

M. G Bubnova

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лабораторией профилактики атеросклероза и тромбоза 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

References

  1. Standards of Medical Care in Diabetes. Diabetes care 2015; 38 (Suppl. 1). doi: 10.2337/dc15-S001
  2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
  3. ACCORD Study Group et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99 (12A): 21i-33i.
  4. Patel A, Chalmers J, Poulter N. ADVANCE: action in diabetes and vascular disease. J Hum Hypertens 2005; 19 (Suppl. 1): S27-32.
  5. Gerstein H.C, Bosch J, Dagenais G.R et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-28.
  6. White W.B, Cannon C.P, Heller S.R et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Мed 2013; 369: 1327-35.
  7. Scirica B.M, Bhatt D.L et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Мed 2013; 369: 1317-26.
  8. Green J.B, Bethel M.A, Armstrong P.W et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Мed 2015; 373 (3): 232-42.
  9. Zinman B, Wanner C, Lachin J.M. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Мed 2015; 373: 2117-28.
  10. Wanner C, Inzucchi S.E, Lachin J.M et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375 (4): 323-34.
  11. Cherney D.Z, Perkins B.A, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129 (5): 587-97.
  12. Skrtic M, Cherney D.Z. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015; 24 (1): 96-103.
  13. Lytvyn Y, Skrtic M, Yang G.K et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308 (2): F77-83.
  14. Ponikowski P, Voors A.A, Anker S.D et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Failure 2016; 18 (8): 891-975.
  15. Verma S, Mazer D, Fitchett D et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMER randomised trial. Diabetologia 2018; doi.org/10.1007/s00125-018-4644-9
  16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. 8-й вып. М.: УП ПРИНТ, 2017. doi: 10.14341/DM20171S8

Copyright (c) 2018 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies